Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Strong 52-week Mirikizumab Phase II data holds promise for Eli Lilly in Crohn’s disease

New data unveiled at the United European Gastroenterology Week (UEGW) virtual conference showed that Eli Lilly’s Crohn’s disease (CD) hopeful, mirikizumab, can deliver durable endoscopic and symptomatic efficacy after 52 weeks in moderate-to-severe patients who had failed or were intolerant to conventional therapy and had failed at least one other biologic agent. mirikizumab’s prospects are favorable in the […]
Read more

Alkermes is expected to expand its presence in the schizophrenia market with its candidate ALKS-3831

Following the announcement of positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the FDA in support of Alkermes’ ALKS-3831 for the treatment of Schizophrenia and Bipolar I Disorder; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and […]
Read more

Breast Cancer Screening Needs to Continue Despite COVID-19

October is Breast Cancer Awareness Month, a worldwide annual campaign that highlights the importance of breast cancer awareness, education and research. One of the consequences of COVID-19 is delays in health checks and preventative screening for cancer, which could result in a huge number of additional cancer casualties, if not managed correctly, says GlobalData, a leading data […]
Read more

Pfizer’s investment in China’s CStone Pharmaceuticals sets stage for first second-generation PD-L1 inhibitor, says GlobalData

Pfizer’s recent investment of $200m in China’s CStone Pharmaceuticals for the development of a second-generation immuno-oncology agent is the latest partnership between US and Chinese companies being utilized as a strategy to develop best-in-class agents to rival the first-in class advantages of currently marketed agents. As a result, there is a clear trend of partnerships […]
Read more

As World Mental Health Day approaches, demand for virtual mental health services still remains high as a result of the COVID-19 pandemic

The COVID-19 pandemic created an unprecedented demand for digital solutions for the delivery of safe and effective mental health treatment such as telemedicine. Even now, seven months after the pandemic started, demand for these services remains high, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “A report […]
Read more

Eli Lilly’s and Regeneron’s EUA applications for their COVID-19 mAb therapies short of clinically relevant data; clinical study participations hampered if process politicized

As US President Donald J. Trump puts his weight behind Eli Lilly and Regeneron Pharmaceuticals’ bid for an FDA Emergency Use Authorization (EUA) for their respective COVID-19 monoclonal antibody (mAb) therapies; Manasi Vaidya and Reynald Castañeda, Pharma Writers for the Investigative News team at GlobalData, offer their view: “Experts we interviewed emphasized the need for […]
Read more

Newly proposed lung cancer screening guidelines will likely drive increase in new cases to over 240,000 by 2025, says GlobalData

Should the latest guidelines proposal by the US Preventive Services Task Force (USPSTF) for the screening of lung cancer take effect, GlobalData epidemiologists predict that the diagnosed incidence of the two main types of lung cancer* will likely surpass the current 2025 estimates of approximately 75 cases per 100,000 population and 13 cases per 100,000 […]
Read more

AstraZeneca’s speedy trial restart splits experts, while Pfizer’s study primed for fast data readout but Moderna may edge it out on detail, says GlobalData

With the European Medicines Agency (EMA) announcing today that it will also initiate a rolling review of the COVID-19 vaccine developed by Pfizer and BioNTech besides just AstraZeneca’s asset; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “After interviewing ten experts, there is clearly a split in terms of […]
Read more

Invokana may experience moderate rebound from decreasing US sales trend following FDA backtracking on boxed warning

The FDA has removed a boxed warning concerning the risk of leg and foot amputations for Janssen’s sodium glucose co-transporter (SGLT) inhibitor, Invokana (canagliflozin) – including its combination varieties Invokamet (canagliflozin + metformin) and Invokamet XR (canagliflozin + metformin extended-release). With the removal of the boxed warning, it is expected that Invokana will experience a […]
Read more
1 … 79 80 81 82 83 … 110